RSV F nanoparticle vaccine

The RSV F nanoparticle vaccine (ResVax) is a recombinant protein subunit vaccine developed by Novavax. It consists of near-full-length, pre-fusogenic respiratory syncytial virus (RSV) fusion (F) glycoprotein trimers that self-assemble into stable protein-detergent nanoparticles, formulated with an aluminum phosphate adjuvant. The vaccine is designed to induce polyclonal neutralizing antibodies targeting antigenic site II and other epitopes on the RSV F protein, which is responsible for viral entry into host cells. ResVax was primarily evaluated in Phase 3 clinical trials (such as the PREPARE trial) for maternal immunization to protect infants from RSV-associated lower respiratory tract infections (LRTI) via passive transfer of maternal antibodies, as well as in older adults. Although it demonstrated some efficacy in reducing severe RSV-associated LRTI and hospitalizations, it failed to meet its primary efficacy endpoints, and its clinical development was subsequently paused.

Brand names

ResVax

Other names

RSV F protein recombinant nanoparticle vaccineRSV F VaccineRSV F-protein nanoparticle vaccineRSV-FRSV-F nanoparticle protein micelle vaccineRSV-F VLP vaccineRespiratory syncytial virus fusion protein virus-like particle vaccineRespiratory syncytial virus vaccine